Some Diabetes Drugs Tied to Lower Risk of Dementia, Parkinson's Disease Sep. 18, 2024 — A class of drugs for diabetes may be associated with a lower risk of dementia and Parkinson's disease ...

Hosted by Kate Harmon and her husband, Matthew Davis, the event − which began after Harmon's father, Bob, was diagnosed with Parkinson’s disease in 2006 − raises awareness and funds for ...

SAN ANTONIO — November is National Diabetes Month, a time when communities across the country seek to bring attention to a ...

Ridgefield closed off Main Street to traffic as more than 1,000 people danced and sang to Taylor Swift’s hit song “Shake It Off” to promote awareness of Parkinson's disease. The event ...

November is National Alzheimer's Disease Awareness Month and National Family Caregivers Month. Maureen McNulty, Alzheimer's Association volunteer and caregiver, joined Fox 5 to talk more about ...

(WTNH) — Today’s health headlines are all about Alzheimer’s Awareness Month. We’re discussing how a common drug for eye diseases could help fight the disease, and a blood test for the ...

What is the history behind naming November as National Alzheimer's Disease Awareness Month? After gaining an understanding of how Alzheimer's disease impacts the affected individual, President ...

MetroWest YMCA Offers Free Programs to Manage and Prevent Chronic Conditions Free Diabetes Prevention Program Starts During ...

protein depletion and heightened risk for fatty liver disease in spinal muscular atrophy (SMA). In honor of Spinal Muscular Atrophy (SMA) Awareness Month, Abraham Homer, MS, the gaming technology ...

Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) a ...

Nov. 12, 2024 — Researchers have identified a potential biomarker of Parkinson's disease progression. According to the new study, patients with a slow progression of ... Oct. 8, 2024 ...

for Alzheimer's disease (“AD”) and Parkinson's disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial ...